Healthcare >> CEO Interviews >> April 6, 2023
Prof. Hartmut J. Ehrlich, M.D., is Chief Executive Officer of Abivax. Prof. Ehrlich is a physician with 30 years of experience in academia and in the biopharmaceutical industry, 20 of which were in product development at Baxter and Sandoz (now Novartis). He has lived and worked in the United States (Eli Lilly and Indiana University, Dept. of Medicine), the Netherlands (Central Laboratory of the Dutch Red Cross), Germany (Max Planck Foundation, Sandoz, Baxter), Switzerland (Sandoz), Austria (Baxter) and France (Abivax). Over the seven years before joining Abivax, Prof. Ehrlich, as Head of Global R&D, successfully built and advanced Baxter BioScience’s R&D portfolio with over 50 programs in preclinical and clinical development. He drove the regulatory approval of key biologics in the specialty areas of hemophilia, thrombosis, immunology, neurology, oncology, biosurgery and vaccines, thereby bringing novel therapies to patients with substantial medical needs. Prof. Ehrlich has authored and co-authored over 120 peer-reviewed articles and book chapters. In 2011, Prof. Ehrlich was named “Professor” by the Austrian President and the Austrian Minister for Science and Research, and he received the title of “Adjunct Professor” of the Danube University Krems, Lower Austria in 2013. Profile Didier Blondel is EVP, Chief Financial Officer and Board Secretary of Abivax. Mr. Blondel was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint venture between Sanofi and Merck, and European leader in human vaccines, since 2012. During the previous 20-year period, Mr. Blondel held a wide scope of senior finance positions at Sanofi, in Commercial Operations and then R&D, where he became Global R&D CFO. He started his career as an auditor at Price Waterhouse Coopers, after graduating from the Commercial Institute of Nancy (ICN), a leading French Business School. He also holds a master in finance and accounting degree from University of Nancy, as well as a Professional Certificate in Finance and Accounting (DESCF). Profile
Word count: 1,906
TWST: For our readers who may not be familiar with your company, can you give us a brief history and overview?
Prof. Ehrlich: Abivax was